HUTCHMED Says Initial Preclinical Data For HMPL-506 Novel, Highly Potent And Differentiated Menin-MLL Inhibitor For The Treatment Of Certain Types Of Acute Leukemia At AACR Congress 2024
HUTCHMED Says Initial Preclinical Data For HMPL-506 Novel, Highly Potent And Differentiated Menin-MLL Inhibitor For The Treatment Of Certain Types Of Acute Leukemia At AACR Congress 2024
Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia. Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models. Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo. The investigational drug candidate displayed favorable pharmacokinetic profiles, high selectivity and low risk of cardiac toxicity. A Phase I study of HMPL-506 is planned for the second half of 2024.
將提供 HMPL-506 的初步臨床前數據，這是一種用於治療某些類型的急性白血病的新型、高效和差異化的 Menin-MLL 抑制劑。與臨床開發中的其他五種腦膜蛋白抑制劑相比，HMPL-506 表現出更強的抑制力 MLL-重新排列和 NPM1 突變白血病細胞系模型。此外，HMPL-506 與阿扎胞苷、venetoclax 或 gilteritinib 聯合使用可協同改善對抗腫瘤的作用 MLL-重新排列了白血病 體外 和 在活體中。該研究候選藥物表現出良好的藥代動力學特徵、高選擇性和低心臟毒性風險。HMPL-506 的一期研究計劃於 2024 年下半年進行。
Initial preclinical data will also be presented for HMPL-A067 (HMA800067), a novel CD38-targeting antibody-drug conjugate (ADC) in which daratumumab was conjugated with cytotoxic payload Monomethyl auristatin E (MMAE) via a novel linker. It demonstrated significant superior anti-tumor activity to daratumumab, including in several B-cell malignancies models with resistance to daratumumab treatment.
還將公佈HMPL-A067（HMA800067）的初步臨床前數據，這是一種靶向CD38的新型抗體藥物偶聯物（ADC），其中達拉妥單抗通過一種新的連接劑與細胞毒性有效載荷單甲基奧利司汀E（MMAE）偶聯。它顯示出優於達拉妥單抗的顯著抗腫瘤活性，包括在幾種對達拉妥單抗治療具有耐藥性的B細胞惡性腫瘤模型中。
Other presentations include preclinical data on the ERK 1/2 inhibitor, HMPL-295; early clinical data on the Syk inhibitor, sovleplenib, in lymphoma patients; additional clinical data from global studies of VEGFR inhibitor, fruquintinib, and MET inhibitor, savolitinib; and several investigator-initiated studies of fruquintinib and VEGFR/CSF-1R/FGFR inhibitor, surufatinib.
其他報告包括ERK 1/2抑制劑 HMPL-295 的臨床前數據；淋巴瘤患者中Syk抑制劑sovleplenib的早期臨床數據；來自VEGFR抑制劑、呋喹替尼和MET抑制劑沃利替尼全球研究的其他臨床數據；以及幾項由研究者發起的呋喹替尼和VEGFR/CSF-1R/FGFR抑制劑surufr抑制劑的研究法替尼。
譯文內容由第三人軟體翻譯。